公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2015 | TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC | Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony | J. Thorac. Oncol. | |||
2015 | TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. | Yang, James Chih-Hsin; Popat, Sanjay; Georgiou, Panos; Miyamoto, Emiko; Isaacson, Jeffrey D.; Wakelee, Heather A. | J. Clin. Oncol. |